[The sustained response rates for chronic hepatitis C patients undergoing therapy with the several interferons and ribavarins supplied by Brazilians Health Ministry is comparable to those reported in the literature].

The sustained response rates of chronic hepatitis C therapy to interferons alpha 2A and 2B associated to ribavirin are described as approximately 40%. Nevertheless, studies on the sustained response rates in a setting of frequent changes of type of interferon as well as of supplies of interferons and ribavirin are lacking.
To evaluate the prevalence of sustained response and to determine the predictors of response to chronic hepatitis C therapy, in a cohort of outpatients at Curitiba, PR, south Brazil, in a setting of heterogeneous therapy regarding type and supply of the medications.
A cohort of 87 chronic hepatitis C patients submitted to therapy with interferon alpha 2 and ribavirin were followed from August 1999 to August 2002. The prevalence of sustained response and the influence of gender, age, genotype and severity of liver fibrosis in the response were evaluated.
A sustained response prevalence of 32.1% was found, positively associated to genotypes 2 and 3.
Despite the frequent changes on product type and/or procedence, the sustained response prevalence rate found in this study was similar to that described in the literature.
AuthorsRafael Nastás Acras, Maria Lúcia A Pedroso, Leiber Carvalho Caum, Júlio C Pisani, Heda M B S Amarante, Eliane R Carmes
JournalArquivos de gastroenterologia (Arq Gastroenterol) 2004 Jan-Mar Vol. 41 Issue 1 Pg. 3-9 ISSN: 0004-2803 [Print] Brazil
Vernacular TitleA taxa de resposta sustentada da hepatite C crônica ao tratamento com os diversos interferons-alfa e ribavirinas distribuídos pelo governo brasileiro é semelhante à da literatura mundial.
PMID15499417 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Antiviral Agents
  • Interferon-alpha
  • Ribavirin
  • Adult
  • Antiviral Agents (therapeutic use)
  • Brazil
  • Cohort Studies
  • Drug Therapy, Combination
  • Fibrosis
  • Genotype
  • Government Programs
  • Hepatitis C, Chronic (drug therapy, genetics)
  • Humans
  • Interferon-alpha (therapeutic use)
  • Liver (pathology)
  • Male
  • Predictive Value of Tests
  • Ribavirin (therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: